Glioblastoma (GBM) remains a deadly tumor. Treatment with chemo-radiotherapy and corticosteroids is known to impair the functionality of lymphocytes, potentially compromising the development of autologous CAR T cell therapies. We here generated pre-clinical investigations of autologous anti-GD2 CAR T cells tested against 2D and 3D models of GBM primary cells. We detected a robust antitumor effect, highlighting the feasibility of developing an autologous anti-GD2 CAR T cell-based therapy for GBM patients.
Autologous anti-GD2 CAR T cells efficiently target primary human glioblastoma / Chiavelli, C.; Prapa, M.; Rovesti, G.; Silingardi, M.; Neri, G.; Pugliese, G.; Trudu, L.; Dall'Ora, M.; Golinelli, G.; Grisendi, G.; Vinet, J.; Bestagno, M.; Spano, C.; Papapietro, R. V.; Depenni, R.; Di Emidio, K.; Pasetto, A.; Nascimento Silva, D.; Feletti, A.; Berlucchi, S.; Iaccarino, C.; Pavesi, G.; Dominici, M.. - In: NPJ PRECISION ONCOLOGY. - ISSN 2397-768X. - 8:1(2024), pp. 1-9. [10.1038/s41698-024-00506-z]
Autologous anti-GD2 CAR T cells efficiently target primary human glioblastoma
Chiavelli C.;Prapa M.;Rovesti G.;Silingardi M.;Neri G.;Pugliese G.;Trudu L.;Dall'Ora M.;Golinelli G.;Grisendi G.;Vinet J.;Spano C.;Depenni R.;Di Emidio K.;Pasetto A.;Iaccarino C.;Pavesi G.;Dominici M.
2024
Abstract
Glioblastoma (GBM) remains a deadly tumor. Treatment with chemo-radiotherapy and corticosteroids is known to impair the functionality of lymphocytes, potentially compromising the development of autologous CAR T cell therapies. We here generated pre-clinical investigations of autologous anti-GD2 CAR T cells tested against 2D and 3D models of GBM primary cells. We detected a robust antitumor effect, highlighting the feasibility of developing an autologous anti-GD2 CAR T cell-based therapy for GBM patients.
Pubblicazioni consigliate
I metadati presenti in IRIS UNIMORE sono rilasciati con licenza Creative Commons CC0 1.0 Universal, mentre i file delle pubblicazioni sono rilasciati con licenza Attribuzione 4.0 Internazionale (CC BY 4.0), salvo diversa indicazione.
In caso di violazione di copyright, contattare Supporto Iris
